- Home
- LDWY vs APRE Comparison
LDWY vs APRE Comparison
Compare LDWY & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- APRE
- Stock Information
- Founded
- LDWY 1990
- APRE 2006
- Country
- LDWY United States
- APRE United States
- Employees
- LDWY N/A
- APRE N/A
- Industry
- LDWY Advertising
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDWY Consumer Discretionary
- APRE Health Care
- Exchange
- LDWY Nasdaq
- APRE Nasdaq
- Market Cap
- LDWY 9.2M
- APRE 9.4M
- IPO Year
- LDWY 1991
- APRE 2019
- Fundamental
- Price
- LDWY $5.15
- APRE $1.47
- Analyst Decision
- LDWY
- APRE Strong Buy
- Analyst Count
- LDWY 0
- APRE 1
- Target Price
- LDWY N/A
- APRE $20.00
- AVG Volume (30 Days)
- LDWY 5.7K
- APRE 34.5K
- Earning Date
- LDWY 08-28-2025
- APRE 11-06-2025
- Dividend Yield
- LDWY N/A
- APRE N/A
- EPS Growth
- LDWY N/A
- APRE N/A
- EPS
- LDWY 1.66
- APRE N/A
- Revenue
- LDWY $71,244,000.00
- APRE $841,012.00
- Revenue This Year
- LDWY N/A
- APRE N/A
- Revenue Next Year
- LDWY N/A
- APRE N/A
- P/E Ratio
- LDWY $3.18
- APRE N/A
- Revenue Growth
- LDWY 187.12
- APRE N/A
- 52 Week Low
- LDWY $3.02
- APRE $1.41
- 52 Week High
- LDWY $6.19
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- LDWY 50.99
- APRE 37.01
- Support Level
- LDWY N/A
- APRE $1.49
- Resistance Level
- LDWY $5.35
- APRE $1.66
- Average True Range (ATR)
- LDWY 0.29
- APRE 0.08
- MACD
- LDWY -0.25
- APRE -0.00
- Stochastic Oscillator
- LDWY 83.20
- APRE 11.41
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.